The top line hasn't knocked your socks off, but certainly they've been good at controlling expenses.

knocked [his] socks off.

In 2005 Nasdaq executed very well to plan, growing the top-line, reducing our baseline expenses and generating a significant increase in net income.

We already assume we have competitive products. But then there's our top line revenue, margin expenses, cost structure, and if we manage those right, we will yield greater (profit) margins.

This is going to set the standards for all the other inhaled insulins that are in development,

It is still too early to know if (Merck) will be able to win cases on a consistent basis,